Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanni Di Perri

Showing results (1-10 of 438) with videos related to

Pageof 44
Sort By:
Le Infezioni in Medicina|December 11, 2023
Pharmacological outlook of Lenacapavir: a novel first-in-class Long-Acting HIV-1 Capsid InhibitorGiovanni Di Perri
Le Infezioni in Medicina|December 18, 2019
Clinical pharmacology of the single tablet regimen bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)Giovanni Di Perri
Le Infezioni in Medicina|June 14, 2020
The rationale for Low-Molecular Weight Heparin (LMWH) use in SARS-CoV-2 infectionGiovanni Di Perri
Le Infezioni in Medicina|February 11, 2022
Tenofovir alafenamide (TAF) clinical pharmacologyGiovanni Di Perri
Le Infezioni in Medicina|December 1, 2020
Tenofovir alafenamide revisitedGiovanni Di Perri
Le Infezioni in Medicina|September 13, 2023
Clinical pharmacology of the SingleTablet Regimen (STR) Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF)Giovanni Di Perri
The Journal of Antimicrobial Chemotherapy|July 30, 2004
Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis?Giovanni Di Perri, Stefano Bonora
Le Infezioni in Medicina|December 18, 2019
ERRATUM Drug-drug interactions in anti-HCV therapy: a comparison among options available in ItalyGiovanni Di Perri, Giuseppe Cariti
Current Opinion in HIV and AIDS|April 18, 2009
Interactions between antiretroviral agents and those used to treat tuberculosisStefano Bonora, Giovanni Di Perri
The New Microbiologica|November 19, 2024
Clinical Pharmacology of the Single Tablet Regimen Bictegravir/Emtricitabine/Tenofovir Alafenamide in the evolving era of antiretroviral therapiesGiovanni Di Perri, Stefano Bonora
Pageof 44

Showing results (1-10 of 438) with videos related to

Sort By:
Pageof 44
Le Infezioni in Medicina|December 11, 2023
Pharmacological outlook of Lenacapavir: a novel first-in-class Long-Acting HIV-1 Capsid InhibitorGiovanni Di Perri
Le Infezioni in Medicina|December 18, 2019
Clinical pharmacology of the single tablet regimen bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)Giovanni Di Perri
Le Infezioni in Medicina|June 14, 2020
The rationale for Low-Molecular Weight Heparin (LMWH) use in SARS-CoV-2 infectionGiovanni Di Perri
Le Infezioni in Medicina|February 11, 2022
Tenofovir alafenamide (TAF) clinical pharmacologyGiovanni Di Perri
Le Infezioni in Medicina|December 1, 2020
Tenofovir alafenamide revisitedGiovanni Di Perri
Le Infezioni in Medicina|September 13, 2023
Clinical pharmacology of the SingleTablet Regimen (STR) Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF)Giovanni Di Perri
The Journal of Antimicrobial Chemotherapy|July 30, 2004
Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis?Giovanni Di Perri, Stefano Bonora
Le Infezioni in Medicina|December 18, 2019
ERRATUM Drug-drug interactions in anti-HCV therapy: a comparison among options available in ItalyGiovanni Di Perri, Giuseppe Cariti
Current Opinion in HIV and AIDS|April 18, 2009
Interactions between antiretroviral agents and those used to treat tuberculosisStefano Bonora, Giovanni Di Perri
The New Microbiologica|November 19, 2024
Clinical Pharmacology of the Single Tablet Regimen Bictegravir/Emtricitabine/Tenofovir Alafenamide in the evolving era of antiretroviral therapiesGiovanni Di Perri, Stefano Bonora
Pageof 44